Furthermore, it has been reported that treatment of cancer cells with HSP inhibitors or proteasome inhibitors results in HSF1 activation and compensatory induction of HSPs thereby reducing the antitumor activity of such inhibitors [134]. This evidence concerns the gene HSP90B2P and cancer.